Loading...
OTCM
MSLPQ
Market cap0kUSD
Mar 05, Last price  
0.00USD
Name

MusclePharm Corp

Chart & Performance

D1W1MN
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-12.49%
Revenues
50m
-22.34%
7,97901,017,9164,047,29520,838,33767,055,215110,877,591177,389,000166,858,000132,499,000102,155,00088,113,00079,667,00064,440,00050,042,000
Net income
-13m
L
-995,890-24,427-1,919,924-20,406,249-26,630,462-26,287,865-17,717,941-13,832,000-51,858,000-3,477,000-10,973,000-10,755,000-18,927,0003,185,000-12,882,000
CFO
-8m
L+826.50%
-961-13,070-1,038,289-3,795,477-5,801,761-697,597-9,972,580-4,133,0005,492,000-15,068,000-5,131,0001,981,000-6,524,000-868,000-8,042,000

Profile

MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada. On December 15, 2022, MusclePharm Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Nevada.
URL
https://musclepharm.com/
IPO date
Dec 03, 2008
Employees
21
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT